Who are Calcium Channel Blockers, ACE-Inhibitor's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/calcium-channel-blockers-ace-inhibitor.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Calcium Channel Blockers, ACE-Inhibitor — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Calcium Channel Blockers, ACE-Inhibitor (Calcium Channel Blockers, ACE-Inhibitor) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination antihypertensive (calcium channel blocker + ACE inhibitor). Area: Cardiovascular.

marketed Combination antihypertensive (calcium channel blocker + ACE inhibitor) L-type calcium channels; Angiotensin-converting enzyme (ACE) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Calcium Channel Blockers, ACE-Inhibitor (Calcium Channel Blockers, ACE-Inhibitor) — University of Aarhus. This combination drug blocks calcium channels to reduce vascular smooth muscle contraction while inhibiting angiotensin-converting enzyme to reduce vasoconstriction and aldosterone secretion, together lowering blood pressure.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Calcium Channel Blockers, ACE-Inhibitor TARGET	Calcium Channel Blockers, ACE-Inhibitor	University of Aarhus	marketed	Combination antihypertensive (calcium channel blocker + ACE inhibitor)	L-type calcium channels; Angiotensin-converting enzyme (ACE)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination antihypertensive (calcium channel blocker + ACE inhibitor) class)

University of Aarhus · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Calcium Channel Blockers, ACE-Inhibitor — Competitive Intelligence Brief. https://druglandscape.com/ci/calcium-channel-blockers-ace-inhibitor. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab